2012
DOI: 10.1111/j.1399-5618.2012.01023.x
|View full text |Cite
|
Sign up to set email alerts
|

Effects of medication on neuroimaging findings in bipolar disorder: an updated review

Abstract: The effects of psychotropic medications, when present, are predominantly normalizing and thus do not seem to provide an alternative explanation for differences in volume, white matter tracts, or BOLD signal between BD participants and healthy subjects. However, the normalizing effects of medication could obfuscate differences between BD and healthy subjects, and thus might lead to type II errors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

17
218
5
15

Year Published

2013
2013
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 342 publications
(255 citation statements)
references
References 158 publications
(205 reference statements)
17
218
5
15
Order By: Relevance
“…However, it seems quite unlikely that the heterogeneous medications within each group would produce the common dimensional effects across groups. Past work has also suggested that medication effects in fMRI studies of mood disorders tend to normalize brain responses (Hafeman et al, 2012), and such effects would not explain the current pattern of results. Third, although the differences we observe between dimensional and categorical analyses suggest distinct and potentially inter-related state and trait abnormalities in reward system function, our cross-sectional sample limits interpretation.…”
Section: Discussioncontrasting
confidence: 45%
“…However, it seems quite unlikely that the heterogeneous medications within each group would produce the common dimensional effects across groups. Past work has also suggested that medication effects in fMRI studies of mood disorders tend to normalize brain responses (Hafeman et al, 2012), and such effects would not explain the current pattern of results. Third, although the differences we observe between dimensional and categorical analyses suggest distinct and potentially inter-related state and trait abnormalities in reward system function, our cross-sectional sample limits interpretation.…”
Section: Discussioncontrasting
confidence: 45%
“…In addition, we could not control for potential effects of medication and its changes over the follow-up period. However, medication has been shown to diminish behavioral and neural differences between patient groups and controls (Hafeman et al, 2012), so that this confound is unlikely to explain our main findings. Further, and this is the major strength of our work, following such patients and obtaining adequate task performance in fMRI condition across several sessions and mood states is rather challenging, but the current study provides an important first attempt to do so.…”
Section: Discussionmentioning
confidence: 80%
“…Another strength is that this study used an unmedicated sample to avoid potential medication confounds. A meta-analysis of studies in BP suggests that psychotropic medications may have normalizing effects on neuroimaging measures that may lead to type II errors, particularly in studies comparing subjects with BP and healthy controls (Hafeman et al, 2012). Future large-scale studies should seek to compare different BP subtypes (for example, type I vs. type II), as well as medication effects on the neural substrates involved in response inhibition.…”
Section: Discussionmentioning
confidence: 99%